Science & Enterprise subscription

Follow us on Twitter

  • Then "Day at the Races"
    about 13 hours ago
  • The Forward, America’s Leading Jewish News Organization, Goes All Digital. Third-generation subscriber here and wor…
    about 15 hours ago
  • Our friends at Statista reported on a survey on how the shutdown is affecting people in the U.S., this weekend's in…
    about 18 hours ago
  • New post on Science and Enterprise: Infographic – Americans Affected by Gov’t Shutdown #Science #Business
    about 18 hours ago
  • New contributed post on Science and Enterprise: Hands Off! Robots in Modern Medicine
    about 19 hours ago

Please share Science & Enterprise

Follow by Email
Visit Us

Spirogen, Genentech Partner on Anti-Cancer Therapies

Beakers and test tubes (Horia Varlan/Flickr)Spirogen Ltd. a London, U.K. biotechnology company, announced a multi-year research collaboration and license agreement with Genentech, a Roche Group company, to discover and develop antibody drug conjugates (ADCs) as potential anti-cancer agents.

The collaboration will make use of Spirogen’s pyrrolobenzodiazepine (PBD) drugs,  a group of natural antibiotics, and associated linking technology. Under the agreement, Spirogen will synthesize and manufacture drug reagents, while Genentech will use Spirogen’s drug reagents to generate ADCs and evaluate their therapeutic potential. Genentech will have an exclusive license to fully develop and commercialize licensed products that contain these ADCs.

Terms of the multi-year collaboration include an initial one-time license fee, development milestones on reaching pre-defined targets, and further milestones and royalties for licensed products. The amounts of those payments were not disclosed.

Photo: Horia Varlan/Flickr

*     *     *

Please share Science & Enterprise ...

2 comments to Spirogen, Genentech Partner on Anti-Cancer Therapies